Krka stock (SI0031102120): solid 2025 dividend proposal and resilient 2024 results

Krka, d. d., Novo mesto has proposed a higher dividend for 2025 and reported resilient 2024 financial results with a strong start to 2025. The Slovenian generic drug maker remains a notable European pharma name for internationally oriented US investors.

Krka, d. d., Novo mesto has drawn investor attention with a higher proposed dividend for 2025 and a resilient performance in its 2024 results, accompanied by a robust first quarter of 2025, according to company disclosures and exchange filings published in recent months, including on the Ljubljana Stock Exchange.

In March 2025, Krka’s management proposed a dividend of EUR 8.20 per share for the 2025 payout, up from EUR 7.50 per share paid for 2024, according to an AGM notice and related materials published on the company’s investor-relations page on March 14, 2025 and reported by the Ljubljana Stock Exchange on the same date, as summarized by Ljubljana Stock Exchange as of 03/14/2025.

For the 2024 financial year, Krka reported revenue growth and solid profitability driven by its generic prescription drugs, with management highlighting particularly strong performance in Central and Eastern Europe and stable demand across key therapeutic areas, based on the company’s annual report and press release dated March 14, 2025, as outlined by Krka investor relations as of 03/14/2025.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Krka
• Sector/industry: Pharmaceuticals, generics
• Headquarters/country: Novo mesto, Slovenia
• Core markets: Europe, including Central and Eastern Europe; selected international markets
• Key revenue drivers: Generic prescription medicines, over-the-counter products, animal health
• Home exchange/listing venue: Ljubljana Stock Exchange (ticker KRKG)
• Trading currency: Euro (EUR)

Krka, d. d., Novo mesto: core business model

Krka, d. d., Novo mesto is one of the largest listed pharmaceutical companies in Central and Eastern Europe, focusing on the development, production and marketing of generic medicines with added value for human and animal health. The group’s portfolio encompasses prescription drugs, over-the-counter medicines and animal health products, with a significant share generated from prescription-only medicines.

The company’s strategy emphasizes vertically integrated operations, spanning research and development, manufacturing and distribution, allowing Krka to control quality and cost across the value chain. This model supports competitive positioning in price-sensitive markets where generics compete with originator drugs and other generic manufacturers.

Krka’s geographic footprint extends from its home base in Slovenia across the European Union, the Western Balkans, Russia and other markets in Eastern Europe, as well as selected overseas territories. The business model leverages a broad sales network and in-house promotion focusing on physicians and pharmacies, while also using local partnerships where necessary to access certain markets and regulatory environments.

Main revenue and product drivers for Krka, d. d., Novo mesto

Krka’s revenue mix is dominated by generic prescription pharmaceuticals in key therapeutic areas such as cardiovascular, central nervous system and gastrointestinal treatments. Management has repeatedly emphasized that products in these segments form the backbone of annual revenue, according to recent annual and interim reports published on the company’s website and regulatory announcements via the Ljubljana Stock Exchange.

Over-the-counter products and animal health medicines provide additional diversification, with branded generics and self-medication products distributed through pharmacies and retail outlets. These segments give Krka exposure to consumer health trends, including demand for vitamins, minerals and lifestyle-related treatments, which can behave differently from prescription drug sales over the economic cycle.

Manufacturing capacity in Slovenia and other locations supports the group’s ability to supply multiple markets simultaneously, while regulatory approvals in the EU and other regions allow Krka to compete in tender-driven systems and reimbursement-based healthcare frameworks. The company’s long-standing presence in Central and Eastern Europe remains an important competitive asset in markets where price pressure is intense and brand recognition of generics can influence prescribing behavior.

Conclusion

Krka, d. d., Novo mesto combines a mature generic pharmaceuticals portfolio with a consistent dividend policy, as evidenced by the proposed higher dividend for 2025 and resilient 2024 financials. For internationally oriented US investors, the stock represents exposure to the European and emerging European healthcare markets through a euro-denominated, Ljubljana-listed name. Key variables to monitor include regulatory developments in core markets, competitive dynamics in generics and the company’s capacity to sustain cash generation supporting both capital expenditure and shareholder distributions over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.